In a study conducted in Italy, 4 of 320 patients—of whom 53% had rheumatoid arthritis and 43% had spondyloarthritis (of these patients, 52% received TNF-α inhibitors, 40% received other bDMARDs, and 8% received targeted synthetic DMARDs [tsDMARDs])—were diagnosed with COVID-19 by rhinopharyngeal swabs. Here, TNF is linked to COVID-19.